CRSF 07th Masterclass Debate: Dr. Sudeep Das vs. Dr. Sandeep Ishi on Neoadjuvant vs. Adjuvant IO

Tune in to a dynamic debate from Day 2 of the Cancer Research and Statistic Foundation (CRSF) 07th Masterclass in Lung Cancer, featuring Dr. Sudeep Das from Kolkata and Dr. Sandeep Ishi from Nashik. The topic of discussion is Resectable Locally Advanced Lung Cancer: 10-Minute Concurrent Chemoradiotherapy (CCRT) Followed by Immuno-Oncology (IO) vs. Neoadjuvant IO Followed by Surgery and Additional IO.
Dr. Sudeep Das presents a case for the traditional approach of 10-minute CCRT followed by IO, emphasizing how this strategy can effectively manage resectable locally advanced lung cancer, providing immediate local control and potentially improving long-term outcomes with subsequent IO therapy.
In contrast, Dr. Sandeep Ishi argues for the emerging approach of neoadjuvant IO followed by surgery, with additional IO treatment, suggesting that pre-surgical immunotherapy can shrink tumors and enhance surgical resectability, while continued IO post-surgery may offer prolonged disease control and improved survival rates.
This engaging debate will delve into the clinical evidence, treatment efficacy, patient outcomes, and the pros and cons of each approach. Both experts bring valuable perspectives on optimizing treatment for locally advanced lung cancer, making this session a must-watch for oncology professionals seeking to understand the latest debates in lung cancer management.
Supported by the Institute of Pulmonology Medical Research & Development and SUNACT, with Sunrise Oncology Centre as the hospital partner, this masterclass highlights the forefront of cancer research and clinical practice.
#LungCancer #OncologyDebate #ImmunoOncology #CRSF #DrSudeepDas #DrSandeepIshi #CancerResearch #NeoadjuvantTherapy #AdjuvantTherapy #CancerTreatment #MedicalInnovation #SunriseOncologyCentre #LungCancerAwareness #CRSFLungCancerMasterclass